Home
BOLD
BOLD News

Latest Boundless Bio Inc. Common Stock (BOLD) News on June 3, 2025

MT Newswires

10 days ago

Boundless Bio's Portfolio Adjustments and Streamlined Operations Boost Cash Runway

Boundless Bio Announces Portfolio Prioritization and Runway Extension

GlobeNewswire

10 days ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know

Zacks

19 days ago

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire

25 days ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

GlobeNewswire

2 months ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

MT Newswires

2 months ago

Boundless Bio Files $400 Million Mixed Shelf

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

GlobeNewswire

2 months ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation

Simply Wall St.

3 months ago

Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation

Boundless Bio to Participate in the Leerink Global Healthcare Conference

GlobeNewswire

3 months ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire

4 months ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Boundless Bio Announces Pipeline and Leadership Updates

GlobeNewswire

6 months ago

Boundless Bio Announces Pipeline and Leadership Updates

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire

6 months ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

7 months ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

GlobeNewswire

7 months ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Boundless Bio Announces Departure of Chief Financial Officer

GlobeNewswire

8 months ago

Boundless Bio Announces Departure of Chief Financial Officer

Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?

Simply Wall St.

8 months ago

Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

GlobeNewswire

9 months ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now?

Insider Monkey

10 months ago

Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now?

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

GlobeNewswire

10 months ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire

a year ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

Business Wire

a year ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Business Wire

a year ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Business Wire

a year ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Business Wire

a year ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Share on Social Networks: